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Abstract 
Background 
In an era of low local relapse rates after adjuvant breast radiotherapy, risks of late normal-
tissue effects (NTE) need to be balanced against risk of relapse. NTE are assessed using 
patient-reported outcome measures (PROMs), clinician-reported outcomes (CRO) and 
photographs. This analysis investigates whether PROMs can be used as primary NTE 
endpoints in breast radiotherapy trials. 
Methods 
Analyses were conducted within IMPORT LOW (ISRCTN12852634) at 2 and 5 years. NTE 
were recorded by CRO, photographs and PROMs. Measures of agreement tested 
concordance, risk ratios for radiotherapy groups were compared, and influence of baseline 
characteristics on concordance investigated.     
Results 
In 1095 patients who consented to PROMS and photographs, PROMs were available at 2 
and/or 5 years for 976 patients, of whom 909 had CRO and 844 had photographs. Few 
patients had moderate/marked NTE, irrespective of method used (eg. 16% patients and 4% 
clinicians reported breast shrinkage at year-5). Patients reported more NTE than assessed 
from CRO or photographs (p<0.001 for most NTE). Concordance between assessments was 
poor on an individual patient level; eg. for year-5 breast shrinkage, % agreement=48% and 
weighted kappa=0.17. Risk ratios comparing radiotherapy schedules were consistent 
between PROMs and CRO or photographs.  
Conclusions 
Few patients had moderate/marked NTE irrespective of method used. Patients reported 
more NTE than CRO and photographs, therefore NTE may be underestimated if PROMs are 
not used. Despite poor concordance between methods, effect sizes from PROMs were 
consistent with CRO and photographs, suggesting PROMs can be used as primary NTE 
endpoints in breast radiotherapy trials.  
250 words 
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Manuscript 
Introduction 
In the current era of low local relapse rates after adjuvant breast radiotherapy (1, 2), the risks 
of radiotherapy-related late normal-tissue effects (NTE) need to be carefully balanced 
against the benefits of treatment, requiring detailed collection of NTE data in breast 
radiotherapy trials. Furthermore, with improvements in breast radiotherapy techniques, 
including the introduction of intensity-modulated (3) and partial-breast radiotherapy (1), the 
NTE event rate has also fallen substantially. Consequently, measuring NTE is becoming 
increasingly challenging.  
NTE have been variously assessed in breast radiotherapy trials using clinician-reported 
outcomes (CRO), photographs and patient-reported outcome measures (PROMs) (2, 3). The 
optimal NTE data collection method is unclear and there is no gold standard. The 
methodology of each assessment type differs. For example, patients may be asked to 
assess changes in their treated breast since their breast cancer treatment, whereas 
clinicians compare the patient’s treated and contralateral breasts. Also, the scales used for 
scoring the different assessments vary.  
Irrespective of differences between the methods, the priorities for breast radiotherapy trials 
are that the method used to detect NTE should be able to differentiate between randomised 
treatment groups (if a difference exists), and that the information obtained is clinically 
relevant to patients. Data from breast radiotherapy trials demonstrate that PROMs are able 
to differentiate between dose/volume regimens (1) and between small dose differences in 
hypofractionated regimens (2). PROMs also provide the patients’ perceptions of the impact 
of their cancer and the consequences of treatment (4) within the framework of the question 
asked. This analysis investigates within the context of the IMPORT LOW partial-breast 
radiotherapy trial, i) the degree of concordance on an individual patient level between 
PROMs and CRO or photographs, ii) whether results for the randomised comparisons 
obtained from PROMs are consistent with those using CRO or photographs and iii) the 
influence of baseline characteristics on concordance, with the overall aim of assessing 
whether PROMs could be used as primary NTE endpoints in future breast radiotherapy 
trials.  
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Methods 
Patient population  
IMPORT LOW (ISRCTN12852634) is a multicentre randomised phase III non-inferiority trial 
comparing safety and efficacy of standard whole-breast radiotherapy with two experimental 
schedules (reduced-dose and partial-breast radiotherapy) in women with low-risk breast 
cancer after breast conserving surgery (1).   
IMPORT LOW included a comprehensive and systematic investigation of NTE including 
CRO in all participants, and PROMs and photographs in a subset of patients for which full 
details of patients and procedures have been published (1).  All centres were invited to 
participate in the PROMs and photographic sub-studies (until sufficient accrual was 
achieved). All patients at these centres were invited to participate in the sub-studies until the 
designated sample size for each sub-study was obtained.  
 
Procedures  
Patients who consented to the PROMs sub-study completed the EORTC QLQ-C30 core 
questionnaire and QLQ-BR23 breast-specific module (5, 6) and 10-item Body Image Scale 
(BIS) (7),  all of which asked patients to consider their symptoms during the past week. The 
Hospital Anxiety and Depression Scale [HADS] (8) and protocol-specific questionnaire items 
relating to ‘change in breast appearance’, ‘breast hardness/firmness’, ‘reduction in size of 
breast’, ‘change in skin appearance’, ‘is the position of the nipple of your affected breast 
different from the other side’, ‘problem getting a bra to fit’ and ‘shoulder stiffness’ which may 
have resulted from any prior breast cancer treatments (2) were also completed. All items 
(with the exception of HADS) were scored on a four-point scale: none, a little, quite a bit, 
very much (interpreted as none, mild, moderate, marked). Questionnaires were completed at 
baseline (pre-radiotherapy) and 6 months, 1, 2 and 5 years after radiotherapy. Patients 
completed PROMs questionnaires alone with no help from clinicians.  
For patients participating in the photographic sub-study, photographs were taken at baseline 
(post surgery but pre-radiotherapy), year-2 and year-5. Change in photographic breast 
appearance of the ipsilateral breast was assessed at 2 and 5 years compared with the 
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baseline photograph. Breast size and surgical deficit were scored from the baseline 
photographs on a 3-point scale (small, medium, large). At 2 and 5 years after radiotherapy, 
breast appearance change (none/ mild/ marked) was scored on a pair of photographs (one 
with the patients’ hands on the hips and one with hands raised) in comparison with the 
baseline photograph. A panel of observers blinded to patient identity, treatment allocation, 
and radiotherapy centre scored the photographs, the methodology having been validated in 
the START pilot trial (9).  
CRO including breast shrinkage, breast induration, telangiectasia and breast oedema were 
scored using the contralateral breast as a comparator with a four-point graded scale (none, a 
little, quite a bit, very much; interpreted as none, mild, moderate, marked) at 1, 2 and 5 years 
following radiotherapy in all patients. The CRO items were established and validated in the 
START trials (10). Clinicians were not blinded to treatment group. 
Statistical analysis 
PROMs were paired with the relevant CRO or photograph at 2 and 5 years for the analyses 
(table 1).  
The “quite a bit” and “very much” categories were combined for PROMs and CRO as few 
NTE were scored as “very much”. This resulted in a 3-point scale corresponding to none, a 
little (mild), quite a bit/very much (moderate/ marked). This also enabled direct comparison 
with photos, also scored on a 3-point scale.  
Agreement between the data ascertainment methods on an individual patient level was 
assessed using percentage agreement (with 95% confidence interval), weighted kappa 
statistic (with 95% confidence interval) and Bowker’s test of symmetry (11). Guidelines for 
interpreting the value of weighted kappa in terms of the strength of agreement are <0.20: 
poor; 0.21-0.40: fair; 0.41-0.6: moderate; 0.61-0.8: good; 0.81-1.00: very good (12). A 
significance level of ≤ 0.005 was used to account for multiple testing in all analyses.  
Risk ratios comparing each test radiotherapy schedule with the control group were 
calculated for each NTE endpoint at year-5 and presented in forest plots for the different 
assessment methods. Results for breast oedema were not included in this comparison as so 
few events were reported using PROMs and CRO at year-5.  
 
The influence of baseline patient characteristics on concordance was investigated using 
stratified analyses, and formally assessed in logistic regression models defining a binary 
outcome as 1=concordant (same scores for PROMs and CRO/ photographs) versus 
6 
 
 
0=discordant (different scores). Baseline factors found to be statistically significantly 
associated with concordance on univariate analysis were tested together on multivariate 
analysis. Baseline characteristics tested included age, treatment group, breast size and 
surgical deficit (assessed from baseline photographs), HADS anxiety and depression 
subscale scores and body image scores.  
 
All analyses were carried out using STATA version 14 based on a database snapshot taken 
on June 15th 2016 (as per the primary endpoint analysis). 
 
Results  
 
2018 patients were recruited to IMPORT LOW from 71 centres. 2 patients requested 
exclusion from analysis. In the 41 centres participating in the PROMs sub-study, 1265/1333 
(95%) patients consented to PROMs, and 1318/1466 (90%) patients consented to the 
photographic sub-study from 37 participating centres. 1095 patients consented to both sub-
studies (figure 1a).  
In 1095 patients who consented to both, PROMs were available at 2 and/ or 5 years for 976 
patients of whom 909 had CRO and 844 had photographs. PROMs, CRO and photographs 
were available for 651 and 518 patients at year-2 (figure 1b) and year-5 respectively (figure 
1c). Separate analyses were conducted in patients with PROMs and CRO, and PROMs and 
photographs, at year-2 and year-5. Data regarding baseline characteristics (1) and PROMs 
questionnaire return rates (13) have been published. 
Overall prevalence of NTE 
The overall prevalence of patients with NTE was low, with most scored as none or mild by all 
three data ascertainment methods (table 2). Few patients had NTE scored as moderate or 
marked. NTE which were commonly reported included breast shrinkage, induration and 
breast appearance change. At year-5, 16% patients and 4% clinicians reported moderate/ 
marked breast shrinkage. With respect to breast induration, 6% patients and 4% clinicians 
reported moderate/ marked changes. For breast appearance change, 13% patients reported 
moderate/ marked changes and photographic assessment reported marked changes in 1%.  
Reporting of NTE by patients versus either CRO or photographs  
Patients reported a higher prevalence of breast changes than CRO and photographs for all 
NTE assessed, except for more clinically-reported mild breast shrinkage compared with 
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patient-reported bra fitting at both time-points (figure 2 and 3). Patients and clinicians 
reported similar prevalences of breast oedema, with very few events at 2 and 5years. 
Concordance between PROMs and CRO or photographs of corresponding NTE on an 
individual patient basis was generally poor (table 2).  
For breast shrinkage at year-5, patients reported more effects than clinicians (figure 3); 
percentage agreement was 48% and concordance was poor as evidenced by the low 
weighted kappa (0.17, table 2). Bowker’s test of symmetry was also highly significant 
(p<0.001) indicating discordance, with patients reporting more effects than clinicians (table 
2). With regard to 5-year breast appearance change, patients reported more NTE than 
scored on photographs (Bowker’s test of symmetry <0.001) [table 2]. Agreement was poor 
(35%), as was concordance (weighted kappa 0.09) [table 2].  
In contrast, for breast induration at year-5, PROMs and CRO appeared better aligned with 
similar levels of effects reported by both (figure 3) and a higher % agreement (61%, table 2), 
but concordance remained poor (weighted kappa 0.12, table 2). In addition, Bowker’s test for 
symmetry was no longer significant (p=0.025), implying similar effects reported by PROMs 
and CRO (table 2).  
Comparison of radiotherapy schedules using PROMs, CRO and photographs 
On comparison of the risk ratios for the radiotherapy schedules, similar effect sizes were 
seen for breast shrinkage and breast appearance change when the analogous question was 
asked of the patient, or ascertained from either CRO or photographs (figure 4). There was 
some evidence of differing effect sizes between the assessment methods for breast 
induration, but the confidence intervals overlapped (figure 4).  
Associations between baseline characteristics and concordance 
On stratified analyses, there was little evidence that concordance varied according to 
baseline characteristics at 2 or 5 years (appendix table 1 & 2). Some baseline factors were 
significantly associated with concordance of PROMs and either CRO or photographs for 
certain NTE in logistic regression models, but predominantly on univariate analysis only and 
not across both time-points (appendix table 3). For example, larger surgical deficit was 
associated with discordance of breast shrinkage at year-5 only [OR 0.32 (95%CI 0.16-0.65)] 
(appendix table 3).  
Discussion 
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This analysis in the context of a randomised trial of partial-breast radiotherapy found few 
patients had moderate/ marked NTE, irrespective of the data ascertainment method used. In 
general, patients reported more NTE compared with clinicians and photographs. 
Concordance was poor between PROMs and either CRO or photographs on an individual 
patient level. However, results obtained for randomised comparisons between treatment 
groups were consistent for PROMs and either CRO or photographs. There were no clinically 
significant associations found between baseline characteristics and concordance of NTE. 
The low overall prevalence of moderate/ marked NTE, irrespective of the data ascertainment 
method used, has been reported in a number of adjuvant breast radiotherapy trials (1, 2, 14). 
It is therefore increasingly important, in an era of improving radiotherapy techniques to 
monitor NTE using sufficiently sensitive methods. Within IMPORT LOW, patients reported 
more NTE compared with clinicians or photographs; this has been previously documented in 
the literature (15-22). This suggests NTE may be underestimated if only clinician-reported or 
photographic outcomes are used. In contrast, the Cambridge IMRT trial (23) found clinicians 
reported a higher prevalence of breast changes than patients which may be related to the 
Cambridge study being a single-centre study with assessments conducted by one individual.  
Concordance was poor on an individual patient level in IMPORT LOW. This could be 
explained by, firstly, the methods not being designed to be interchangeable given the 
different comparators used. Secondly, each method is also asking a slightly different 
question; when patient-reported bra fitting was compared with clinician-reported breast 
shrinkage, patients were deciding what is a reasonable fit in general, whereas clinicians 
reported degree of breast shrinkage. Thirdly, each method has its own scoring sub-scale 
which may be worded and categorised differently. Poor concordance has been consistently 
reported in the literature to date (15-17, 23-26). Furthermore, it has been argued that some 
variation is ‘quite acceptable and comprehensible’ due to the methodological differences 
between toxicity scoring by patients and clinicians (27). 
Although concordance was poor on an individual patient level, the three methods generated 
similar estimates of effect sizes in terms of comparisons between the randomised 
treatments, suggesting it is reasonable to use any method. These findings are consistent 
with those from the START trials (15). Within IMPORT LOW there also appeared to be a 
higher sensitivity of PROMs to treatment volume, although the effect sizes obtained from 
PROMs remained consistent with CRO and photographs. It should be noted that the PROMs 
investigated in this analysis and the START trials were the protocol-specific items, which 
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were specifically developed to capture late radiotherapy effects (15), rather than generic 
PROMs related to general quality of life  (5).  
With respect to the influence of baseline characteristics on concordance, findings were not 
consistent across NTE or years of assessment and most associations found were significant 
on univariate analysis only. It is therefore not possible to draw any firm conclusions from 
these data. The START (15) and Cambridge IMRT (23) trials found no evidence of 
associations between baseline factors and concordance of NTE assessment methods.  
In relation to which NTE assessment methods to use in future breast radiotherapy trials, 
each has advantages and disadvantages. Clinicians are able to assess the breast with a 3-D 
view whereas this is not possible with standard photographs (unless taken from various 
angles providing an overall composite of the breast, although limited resources may prevent 
this). However, there is a risk of ‘bias reporting’, as clinicians cannot be blinded to the 
allocated radiotherapy treatment. Also, varying thresholds of experience in grading toxicity 
between clinicians can lead to interobserver variability; there was no formal training protocol 
for clinicians assessing NTE in IMPORT LOW. Furthermore, changes in UK working 
practices including earlier discharge of patients back to primary care make hospital-based 
follow-up challenging (28).  
Obtaining photographs is also becoming increasingly challenging. Firstly, despite consenting 
to participate in a photographic sub-study, patients may not attend for photographs. There is 
a risk of ‘informative censoring’ where patients may choose not to attend for photographs  
either 1) because they do not think there is a problem with their treated breast or 2) they may 
have experienced NTE and feel uncomfortable about having photographs, resulting in a self-
selected population. Of note there was no evidence of change in attendance for year-5 
photographs based on year-2 photograph scores in IMPORT LOW. Additionally, workforce 
changes including closure of medical photography departments make it harder to schedule 
photographs. It should be noted that photographs provide the only unbiased comparison of 
NTE between randomised treatment groups (1-3, 23) as the panel of clinicians scoring 
photographs are blinded to treatment allocation. Photographs also provide a permanent 
record at a fixed time point and can be filed and stored for future use. Scoring can also be 
validated by repeat scoring from different observers (9). However, in IMPORT LOW, there 
was a large discrepancy in rating overall change in breast appearance between photographs 
and PROMs (% agreement = 26% and 35% at year-2 and 5 respectively). Patients reported 
significantly more NTE at both time-points, suggesting photographs may not capture the 
changes which are important for patients.  
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PROMs provide an opportunity to understand the patients’ own perception of  NTE within the 
framework of questions asked. We know that patients report more NTE than clinicians (15-
22) or photographs and therefore, without the use of PROMs, the prevalence of NTE may be 
underestimated. Furthermore, PROMs are able to distinguish between treatment groups (1, 
2). Within the START trials, all three data ascertainment methods were able to differentiate 
between randomised treatment groups (29, 30) whereas in IMPORT LOW it was found that 
only PROMs were able to distinguish between randomised comparisons (1). This difference 
in findings is likely related to the NTE event rate being lower in IMPORT LOW than in the 
START trials. In future breast radiotherapy trials (with expected low NTE rates), PROMs may 
have better capability in differentiating between treatment groups.  
However, there are a number of issues related to PROMs. Firstly, certain patient groups may 
not wish to participate in a PROMs study resulting in a trial population unrepresentative of 
the general population. Secondly, obtaining complete datasets can be challenging (4) as 
questionnaires may not be returned and individual questions may not be completed. Thirdly, 
there is a risk of bias related to questionnaire return as patients who return questionnaires 
may have different characteristics to those who don’t and may report either more or fewer 
side-effects. In IMPORT LOW, women who declined participation in the PROMs sub-study 
were slightly older than those who did consent (13). There were no significant differences in 
the majority of baseline characteristics in those who did or did not return questionnaires at 5 
years, with the exception of higher baseline HADS anxiety and depression subscale scores 
in patients who did not return their year-5 questionnaire (13). Also, patients who reported 
more adverse effects at year-2 were more likely to return questionnaires at year-5 (13). The 
prevalence of NTE at individual time-points may therefore be overestimated. Finally, 
irrespective of missing data, there is also risk of ‘bias reporting’, as patients cannot be 
blinded to treatment group in radiotherapy trials. Although the risk of bias reporting cannot 
be avoided, strategies can be implemented to reduce missing data, including collecting data 
electronically, such as  via smart phone/  email. Reducing numbers of questions in PROM 
questionnaires to include only the most salient and discriminating questions may also 
improve return rates. As well as obtaining complete and unbiased data-sets for PROMs, 
improvements in the standardisation of analysis, interpretation and reporting of PROMs data 
in clinical trials are also required to enable cross-comparison of data between trials (31).  
We have discussed whether PROMs could potentially replace either CRO or photographs to 
assess NTE. Broadly, patients rate their subjective satisfaction with an experience of a range 
of breast changes, whilst clinicians seek objective adverse treatment effects. Therefore, the 
differences and agreements found by the methods contribute to the overall trial evaluation 
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from multiple perspectives, affecting both the individual patient and randomised trial 
population. We acknowledge CRO are still widely supported and an alternative viewpoint is 
that both PROMs and CROs may be necessary as they measure differing aspects of 
disease experience and are complementary (32). 
The main limitation of this analysis is that the IMPORT LOW trial was not designed to 
address the specific question of concordance between the data ascertainment methods 
therefore methodological issues regarding data ascertainment exist. These include each of 
the methods asking a slightly different question and using different comparators, with various 
subscales. The lack of standardisation between the methods may limit comparability 
between PROMs and either CRO or photographs.  
Few patients had moderate/marked NTE irrespective of method used. Patients reported 
more NTE than CRO and photographs, therefore NTE may be underestimated if PROMs are 
not used. Despite poor concordance between assessment methods, effect sizes from 
PROMs were consistent with CRO and photographs, suggesting PROMs can be used as 
primary NTE endpoints in breast radiotherapy trials.  
 
 
Figure Captions 
Figure 1: Summary of whole trial population consenting to PROMs and photographs, and 
data available at 2 and 5 years 
 
Figure 2: Comparison of year-2 patient reported outcome measures, clinician and 
photographic assessments of specific late NTE in IMPORT LOW 
 
Figure 3: Comparison of year-5 patient reported outcome measures, clinician and 
photographic assessments of specific late NTE in IMPORT LOW 
 
Figure 4: Comparison of the estimates of effect sizes for the randomised radiotherapy 
groups between PROMs and CRO/photographs at 5 years 
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